![]() ![]() However, until such breakthrough therapies are available to the majority of patients, antibody therapeutics will be on the shelf, continuing to provide therapeutic benefits. The recent approval of ocular gene therapy for inherited disease offers new hope in this direction. Unlike IVT frequent injections, molecular therapies such as cell therapy and gene therapy offer restoration ability hence gained a lot of traction. Most of these strategies aim to reduce the frequency of injections, thereby increasing patient compliance and reducing patient-associated burden. To address these challenges, numerous technologies and therapies are under development. Biologics and small molecules offer efficacy but relatively shorter half-life after intravitreal injections. Intravitreal (IVT) injections are popular clinical option. There was no statistically significant difference in the proportion of patients who had zero anterior chamber cell at post-operative month 1 between groups.Īge-related macular degeneration (AMD) is the leading cause of vision loss in geriatric population. Mean post-operative IOP for the topical group at months 1 and 3 was 17.6☖.4 and 15.1☓.1, respectively and the dexamethasone group, 17.5±4.8 and 15.0☓.4, respectively P=0.772 and 0.884. Mean pre-operative IOP for the topical group was 18.8±5.5 and the dexamethasone group was 17.1±4.1,P=0.064. 70% of patients in the topical group had zero anterior chamber cell at post-operative month 1 compared to 75.8% in the dexamethasone group,P=0.583. Mean post-operative inflammatory cell for the topical group at month 1 was 0.2☐.3, and the dexamethasone group, 0.3☐.5 P=0.816. Post-operative IOP and rate of cystoid macular edema (CME) were recorded at months 1 and 3.Ĥ0 eyes receiving topical prednisolone were compared to 35 eyes receiving a dexamethasone insert after iStent or Hydrus insertion. Post-operative inflammatory cell and the proportion of patients with zero anterior chamber cells was recorded at month 1. Patients receiving a dexamethasone insert after iStent or Hydrus insertion were included and compared to age-matched controls who received topical prednisolone. To compare post-operative inflammation in patients who received an intracanalicular dexamethasone insert or topical prednisolone after iStent or Hydrus surgery. ![]() Using an intracanalicular dexamethasone insert or topical prednisolone following iStent and Hydrus surgery provided similar short-term control of post-operative inflammation. ![]()
0 Comments
Leave a Reply. |